Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Elizabeth Berry

Nurse Practitioner, Psychiatric/Mental Health Creve Coeur, MO Nurse Practitioner

NPI 1134847304 CMS profile 11362868

11477 Olde Cabin Rd 140, Creve Coeur, MO 63141

Open in the dashboard

General payments

$8,647

324 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Elizabeth Berry of Creve Coeur, MO is reported in the CMS Open Payments database as having received $8,647 across 324 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,388 141
2024 General $2,660 98
2023 General $2,421 79
2022 General $178 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elizabeth Berry
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Elizabeth Berry were reported at $3,388. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Elizabeth Berry Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $166 $54–$482 $132
2022 $178 $195 $66–$559 $149
2023 $2,421 $233 $82–$673 $160
2024 $2,660 $236 $84–$688 $164
2025 $3,388 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Otsuka America Pharmaceutical, Inc. $1,228 36 payments
  2. Teva Pharmaceuticals USA, Inc. $1,091 36 payments
  3. AbbVie, Inc. $1,001 37 payments
  4. ITI, Inc. $875 29 payments
  5. E.R. Squibb & Sons, L.L.C. $742 16 payments
  6. Axsome Therapeutics, Inc. $645 21 payments
  7. Alkermes, Inc. $609 37 payments
  8. Neurocrine Biosciences, Inc. $441 12 payments
  9. Lundbeck LLC $420 24 payments
  10. Vanda Pharmaceuticals Inc. $377 23 payments
  11. Other $1,219 53 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $8,647 324 payments
Products named General payments · program years 2022–2025
  1. REXULTI Psychiatry $845 29 payments
  2. CAPLYTA $780 24 payments
  3. Auvelity $645 21 payments
  4. VRAYLAR $628 23 payments
  5. Austedo XR $605 19 payments
  6. LYBALVI $599 36 payments
  7. COBENFY $590 13 payments
  8. UZEDY $468 14 payments
  9. INGREZZA $441 12 payments
  10. REXULTI Psychiatry $420 24 payments
  11. Other $5,429 270 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

1,057

Median for Nurse Practitioner: 389

Drug cost

$157,362

Median for Nurse Practitioner: $21,885

Branded share of claims

24.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rexulti Brexpiprazole Brand 32 $56,520
Uzedy Risperidone Brand 12 $44,009
Vraylar Cariprazine Hcl Brand 18 $27,472
Divalproex Sodium Er Divalproex Sodium Brand 29 $4,799
Memantine Hcl Er Memantine Hcl Brand 55 $4,682
Hydroxyzine Hcl Generic 118 $3,260
Aripiprazole Generic 40 $1,805
Sertraline Hcl Generic 76 $1,765
Mirtazapine Generic 68 $1,516
Trazodone Hcl Generic 68 $1,502

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$14,379

Medicare's payments for the services billed

Medicare patients

52

Average age 68

Services billed

223

30 women, 22 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 75%
Arthritis 48%
Alzheimer's or dementia 40%
Diabetes 33%
Chronic kidney disease 29%
Heart failure 23%
COPD 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $272
  • Lundbeck LLC $173
$445 32 —
VRAYLAR
  • AbbVie, Inc. $330
$330 18 —
CAPLYTA
  • ITI, Inc. $318
$318 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $295
$295 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $209
$209 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

324 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record